Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis

被引：0
|
作者：
Qi Pei
Lu Huang
Jie Huang
Jing-kai Gu
Yun Kuang
Xiao-cong Zuo
Jun-jie Ding
Hong-yi Tan
Cheng-xian Guo
Shi-kun Liu
Guo-ping Yang
机构：
[1] Third Xiangya Hospital,Center of Clinical Pharmacology and Pharmacy Department
[2] Central South University,undefined
[3] Drug Metabolism Research Center of Jilin University,undefined
[4] Children's Hospital of Fudan University,undefined
来源：
Acta Pharmacologica Sinica | 2016年 / 37卷
关键词：
schizophrenia; iloperidone; gene polymorphisms; 10; population pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1499 / 1508
页数：9
相关论文
共 50 条
  • [1] Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis
    Pei, Qi
    Huang, Lu
    Huang, Jie
    Gu, Jing-kai
    Kuang, Yun
    Zuo, Xiao-cong
    Ding, Jun-jie
    Tan, Hong-yi
    Guo, Cheng-xian
    Liu, Shi-kun
    Yang, Guo-ping
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (11) : 1499 - 1508
  • [2] The association between CYP2D6 genetic polymorphism and schizophrenia in a Chinese population
    Zhou, Jian
    Wang Yajie
    Wang, Gang
    Chen Xueyan
    Lv, Hong
    Kang Xixiong
    PROGRESS ON POST-GENOME TECHNOLOGIES, 2007, : 453 - 455
  • [3] Influence of CYP2D6 polymorphisms on symptomatology and sideeffects of patients with schizophrenia in Malaysia
    Zahari, Zalina
    Salleh, Mohd Razali
    Teh, Lay Kek
    Ismail, Rusli
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2009, 16 (03): : 13 - 21
  • [4] A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia
    Locatelli, Igor
    Kastelic, Matej
    Koprivsek, Jure
    Kores-Plesnicar, Blanka
    Mrhar, Ales
    Dolzan, Vita
    Grabnar, Iztok
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 41 (02) : 289 - 298
  • [5] CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia:: a meta-analysis
    Patsopoulos, NA
    Ntzani, EE
    Zintzaras, E
    Ioannidis, JPA
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (03): : 151 - 158
  • [6] Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan
    Chen, CH
    Hung, CC
    Wei, FC
    Koong, FJ
    PSYCHIATRIC GENETICS, 2001, 11 (03) : 153 - 155
  • [7] Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
    Kapitany, T
    Meszaros, K
    Lenzinger, E
    Schindler, SD
    Barnas, C
    Fuchs, K
    Sieghart, W
    Aschauer, HN
    Kasper, S
    SCHIZOPHRENIA RESEARCH, 1998, 32 (02) : 101 - 106
  • [8] CYP2D6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia
    Zeng, Lei
    Kang, ChuanYuan
    Yuan, Jing
    Zhang, Yan
    Wei, Yujun
    Xu, Li
    Zhou, Fang
    Yang, JianZhong
    SCHIZOPHRENIA RESEARCH, 2017, 188 : 50 - 51
  • [9] Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study
    Ito, Takahiro
    Yamamoto, Kazuhiro
    Ohsawa, Fuminori
    Otsuka, Ikuo
    Hishimoto, Akitoyo
    Sora, Ichiro
    Hirai, Midori
    Yano, Ikuko
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2018, 4
  • [10] Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study
    Takahiro Ito
    Kazuhiro Yamamoto
    Fuminori Ohsawa
    Ikuo Otsuka
    Akitoyo Hishimoto
    Ichiro Sora
    Midori Hirai
    Ikuko Yano
    Journal of Pharmaceutical Health Care and Sciences, 4 (1)
12345